| Net Loss Per Share The Company reports both basic net loss per share, which is based on the weighted-average number of common shares outstanding during the period, and diluted net loss per share, which is based on the weighted-average number of common shares outstanding and potentially dilutive shares outstanding during the period.
The computations of basic and diluted net loss per share are presented in the following table (in thousands, except per share amounts): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended | | Nine Months Ended | | | | | October 31, 2020 | | November 2, 2019 | | October 31, 2020 | | November 2, 2019 | | | | | | Numerator: | | | | | | | | | | | | | Net loss | $ | (22,908) | | | $ | (82,501) | | | $ | (293,834) | | | $ | (188,282) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Denominator: | | | | | | | | | | | | | Weighted-average shares — basic | 670,487 | | | 668,178 | | | 667,186 | | | 667,184 | | | | | | | Effect of dilutive securities: | | | | | | | | | | | | | Share-based awards | — | | | — | | | — | | | — | | | | | | | Weighted-average shares — diluted | 670,487 | | | 668,178 | | | 667,186 | | | 667,184 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Net loss per share: | | | | | | | | | | | | | Basic | $ | (0.03) | | | $ | (0.12) | | | $ | (0.44) | | | $ | (0.28) | | | | | | | Diluted | $ | (0.03) | | | $ | (0.12) | | | $ | (0.44) | | | $ | (0.28) | | | | | |
Potential dilutive securities include dilutive common shares from share-based awards attributable to the assumed exercise of stock options, restricted stock units and employee stock purchase plan shares using the treasury stock method. Under the treasury stock method, potential common shares outstanding are not included in the computation of diluted net income per share if their effect is anti-dilutive.
Anti-dilutive potential shares are presented in the following table (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended | | Nine Months Ended | | | October 31, 2020 | | November 2, 2019 | | October 31, 2020 | | November 2, 2019 | | Weighted-average shares outstanding: | | | | | | | | | Share-based awards | 12,456 | | | 13,000 | | | 10,401 | | | 13,380 | |
Anti-dilutive potential shares from share-based awards are excluded from the calculation of diluted earnings per share for all periods reported above because either their exercise price exceeded the average market price during the period or the share-based awards were determined to be anti-dilutive based on applying the treasury stock method. Anti-dilutive potential shares from share based awards are excluded from the calculation of diluted earnings per share for the three and nine months ended October 31, 2020 and November 2, 2019 due to the net losses reported in those periods.
|